CN1861114A - Application of Qishen Yidripping pills for preparing medicine for preventing and treating high-altitude oxygen deficit - Google Patents
Application of Qishen Yidripping pills for preparing medicine for preventing and treating high-altitude oxygen deficit Download PDFInfo
- Publication number
- CN1861114A CN1861114A CN 200510013506 CN200510013506A CN1861114A CN 1861114 A CN1861114 A CN 1861114A CN 200510013506 CN200510013506 CN 200510013506 CN 200510013506 A CN200510013506 A CN 200510013506A CN 1861114 A CN1861114 A CN 1861114A
- Authority
- CN
- China
- Prior art keywords
- qishen
- radix
- qishen yiqi
- yiqi diwan
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 239000006187 pill Substances 0.000 title abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title description 13
- 229910052760 oxygen Inorganic materials 0.000 title description 13
- 239000001301 oxygen Substances 0.000 title description 13
- 230000006735 deficit Effects 0.000 title 1
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 37
- 206010002660 Anoxia Diseases 0.000 claims abstract description 15
- 241000976983 Anoxia Species 0.000 claims abstract description 15
- 230000007953 anoxia Effects 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims description 24
- 239000009636 Huang Qi Substances 0.000 claims description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 18
- 241000180649 Panax notoginseng Species 0.000 claims description 18
- 239000008412 qishen yiqi Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 38
- 230000007954 hypoxia Effects 0.000 description 22
- 235000014655 lactic acid Nutrition 0.000 description 19
- 239000004310 lactic acid Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 13
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 10
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An application of the 'Qi-replenishing' Qishen dripping pill in preparing the medicines for preventing and treating altitude anoxia is disclosed.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to the application of QISHEN YIQI DIWAN in preparation prevention and treatment high altitude anoxia medicine.
Background technology
The change of aspects such as the function of human body that the anoxia in the altitude environment due to the oxygen supply deficiency can cause, metabolism and form, but threat to life when serious.Common people step into altitude environment for the first time, the adaptability compensation response of each organ of human body and tissue at first can occur, accelerate as exaggerated respiration, and increased heart rate, vasoconstrictions such as skin gastrointestinal kidney, and cerebrovascular and crown arteriectasia, or the like.Need by the above-mentioned compensatory homergy that still can not keep human body, just need treatments such as artificial oxygen uptake.If can't correct its anoxybiotic words, will make each nerve centre enter inhibitory state because of central nervous system's anoxia, feasible breathing shoals, slack-off, heart rate reduces and kinemic decline, pulmonary edema, monge disease, myocardial infarction, cerebral thrombosis, cerebral edema, in addition dead.The high altitude anoxia most people can be regulated by self and adapt to gradually, have only the sub-fraction people can produce a series of clinical manifestation.However, high altitude anoxia is prevented and treated still seem extremely important early.
QISHEN YIQI DIWAN is made up of the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng and Lignum Dalbergiae Odoriferae, in order to the angina pectoris of treatment coronary heart disease with qi deficiency and blood stasis.Chinese patent CN1375316A discloses composition, method for making and the purposes aspect angina pectoris of said preparation, but this medicine does not appear in the newspapers as yet in the effect that prevents and treats aspect the high altitude anoxia.
Summary of the invention
The purpose of this invention is to provide QISHEN YIQI DIWAN and prevent and treat application in the high altitude anoxia medicine in preparation.
QISHEN YIQI DIWAN is to be prepared from by following component by weight percentage: the Radix Astragali 22.2%～66.8%, Radix Salviae Miltiorrhizae 11.6%～33.4%, Radix Notoginseng 2.5%～13.5%, Lignum Dalbergiae Odoriferae 14.5%～44.3%.Its best proportioning is the Radix Astragali 44.7%, Radix Salviae Miltiorrhizae 26.7%, Radix Notoginseng 6.3%, Lignum Dalbergiae Odoriferae 22.3%; Perhaps with the Radix Astragali 41.2%, Radix Salviae Miltiorrhizae 23.8%, Radix Notoginseng 4.5%, Lignum Dalbergiae Odoriferae 30.5%.
For a better understanding of the present invention, below by the experiment of QISHEN YIQI DIWAN, illustrate that QISHEN YIQI DIWAN is in the effect that prevents and treats aspect the high altitude anoxia to the influence of malonaldehyde (MDA), lactic acid content in simulation 7500 meters hypoxia rat cerebral tissues of height above sea level and the blood.
One, method
1. animal is handled: 30 of (1) SD rats, body weight 180～200g is divided into normal oxygen matched group (n=10), acute hypoxia group (n=10), QISHEN YIQI DIWAN at random and adds hypoxia group (n=10).QISHEN YIQI DIWAN adds hypoxia group by 0.8ml/100g body weight (be 30mg QISHEN YIQI DIWAN/100g body weight, use water dissolution) dosage gastric infusion every day 1 time, continuous 7 days; All the other two groups give isopyknic water.(2) decompression method: acute hypoxia group and QISHEN YIQI DIWAN add the hypoxia group animal and placed in the lower pressure environment tank in 1 hour after the administration the last time, rise to 7500 meters of height above sea level with the speed of 10 meter per seconds, continue 7 hours; Normal oxygen matched group is left intact, and normal oxygen room temperature is raised.Behind the deliver from vault each treated animal break end rapidly the stripping brain, get blood.Wherein half brain is used for the mensuration of brain water content, makes 5% brain homogenate by the normal saline of 0～4 ℃ of 1: 20 (w/v) adding after half brain is weighed in addition.Centrifugal blood is got serum.
2. brain water content is measured: with doing wet mass method, each is organized half side cerebral tissue and places weighing botle, weighs to be placed on 50 ℃ of stove-dryings to constant weight.By formula calculate brain water content: brain water content (%)=(wet weight-dry weight)/wet weight * 100%.
3. biochemical measurement: measure the brain homogenate protein content with Folin-phenol method.Get 5% brain homogenate, each 100 μ l mensuration MDA content of serum; MDA content is represented with nmol/mgprot in the tissue, and MDA content is represented with nmol/ml in the serum.Get 5% brain homogenate, each 10 μ l mensuration lactic acid content of serum; Lactic acid content represents that with μ mol/mgprot lactic acid content is represented with mmol/L in the serum in the tissue.
4. statistical method: every group of experimental result represent with x ± s, respectively organizes the significance of difference between the mean with the t check.
Two, result
1. the variation of brain tissue homogenate's water content, MDA and lactic acid content (seeing Table 1)
The normal oxygen matched group of acute hypoxia group brain water content significantly increases (P＜0.01), and MDA and lactic acid content obviously increase (P＜0.01); Brain water content, MDA and lactic acid content that QISHEN YIQI DIWAN adds hypoxia group obviously reduce (P＜0.05 or P＜0.01) than the acute hypoxia group.
The variation of table 1 brain tissue homogenate water content, MDA, lactic acid content (x ± s)
| Group | Water content (%) | MDA(nmol/mgprot) | Lactic acid (μ mol/mgprot) |
| Normal oxygen matched group | 78.06±0.192 | 6.042±0.845 | 0.155±0.034 |
| The acute hypoxia group | 78.71±0.221 ** | 7.483±0.747 ** | 0.239±0.041 ** |
| QISHEN YIQI DIWAN adds hypoxia group | 78.38±0.281 **## | 6.753±0.426 *# | 0.178±0.039 ## |
Annotate: compare with normal oxygen matched group,
*P＜0.05
*P＜0.01
Compare with the acute hypoxia group,
#P＜0.05
##P＜0.01
2. the variation of MDA and lactic acid content in the serum (seeing Table 2)
The normal oxygen matched group of MDA and lactic acid content significantly increases (P＜0.01) in the acute hypoxia group serum, and QISHEN YIQI DIWAN adds that MDA and lactic acid content significantly reduce (P＜0.01) than the acute hypoxia group in the hypoxia group serum.
The variation of MDA, lactic acid content in table 2 serum (x ± s)
| Group | MDA(nmol/ml) | Lactic acid (mmol/L) |
| Normal oxygen matched group | 7.562±0.985 | 9.414±1.122 |
| The acute hypoxia group | 10.138±1.241 ** | 10.987±1.124 ** |
| QISHEN YIQI DIWAN adds hypoxia group | 7.112±0.973 ## | 8.763±1.257 ## |
Annotate: compare with normal oxygen matched group,
*P＜0.05
*P＜0.01
Compare with the acute hypoxia group,
#P＜0.05
##P＜0.01
Hypoxia causes that the process of glucose anerobic glycolysis in cerebral tissue and the blood strengthens, and lactic acid generates to be increased.Lactic acid gathers at tissue and can cause Premeabilisation of cells to be pressed increasing, and mitochondrial swelling and breaking influences the mitochondrial respiratory function and energy metabolism takes place falls and hinder.Lactic acid and oxygen-derived free radicals and lipid peroxide generation increase in the born of the same parents can damage mitochondrial energy metabolism again during hypoxia, and the ATP level descends in the born of the same parents.In the above-mentioned experiment, lactic acid and MDA content obviously increase in rat cerebral tissue and the blood after exposed hypoxia, and give in advance before the hypoxia that QISHEN YIQI DIWAN can suppress lactic acid and MDA content increases.This result shows, and QISHEN YIQI DIWAN has the ATP of promotion generative capacity, can be used for preventing and treating high altitude anoxia.
The specific embodiment
Below in conjunction with embodiment medicine of the present invention is described further, following each embodiment only is used to the present invention is described and is not limitation of the present invention.
Embodiment one
Get Radix Astragali 86.5g, Radix Salviae Miltiorrhizae 21.3g, Radix Notoginseng 3.5g, Lignum Dalbergiae Odoriferae 20.6g, adjuvant Polyethylene Glycol-6000 30g.Will be through Radix Salviae Miltiorrhizae, the Radix Notoginseng of pulverizing, decocting boils 2 times, adds 7 times of water gagings at every turn, each 2 hours, merge decoction liquor, filter, filtrate is concentrated into 900ml, add 95% ethanol, make determining alcohol reach 70%, left standstill 12～24 hours, filter, reclaim ethanol, being condensed into relative density is the extractum of 1.32～1.38 (50～60 ℃); To decoct with water 2 times through the Radix Astragali of pulverizing, add 6 times of water gagings at every turn, extracted successively 2 hours, 1 hour, merging filtrate is when being concentrated into the 1500ml left and right sides, adding 95% ethanol, to make determining alcohol be 60%, left standstill 12～24 hours, filters, filtrate recycling ethanol, when being concentrated into the 400ml left and right sides, adding 95% ethanol, to make determining alcohol be 80%, left standstill 12～24 hours, filter, filtrate recycling ethanol, being condensed into relative density is the extractum of 1.32～1.38 (50～60 ℃); Get Lignum Dalbergiae Odoriferae, add 5 times of water gagings, reflux, extract, 5 hours is collected volatile oil; Get above-mentioned Salvia miltiorrhiza and Panax notoginseng extractum, Radix Astragali extractum and Polyethylene Glycol-6000, water-bath is dissolved, and after change is even, adds volatile oil of Lignum Dalbergiae Odoriferae, and mixing moves in the drop pill machine, makes 1000 drop pill.
Embodiment two
Get Radix Astragali 40.6g, Radix Salviae Miltiorrhizae 44.8g, Radix Notoginseng 11.2g, Lignum Dalbergiae Odoriferae 38.6g, adjuvant Polyethylene Glycol-6000 30g makes Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment three
Get Radix Astragali 77.3g, Radix Salviae Miltiorrhizae 22.8g, Radix Notoginseng 4.8g, Lignum Dalbergiae Odoriferae 30.5g, adjuvant Polyethylene Glycol-6000 28g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment four
Get Radix Astragali 42.3g, Radix Salviae Miltiorrhizae 39.2g, Radix Notoginseng 8.2g, Lignum Dalbergiae Odoriferae 46.8g, adjuvant Polyethylene Glycol-6000 25g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment five
Get Radix Astragali 65.2g, Radix Salviae Miltiorrhizae 38.9g, Radix Notoginseng 9.3g, Lignum Dalbergiae Odoriferae 32.5g, adjuvant Polyethylene Glycol-6000 40g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment six
Get Radix Astragali 56.2g, Radix Salviae Miltiorrhizae 32.5g, Radix Notoginseng 6.2g, Lignum Dalbergiae Odoriferae 41.6g, adjuvant Polyethylene Glycol-6000 22g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment seven
Get Radix Astragali 36.5g, Radix Salviae Miltiorrhizae 32.4g, Radix Notoginseng 6.2g, Lignum Dalbergiae Odoriferae 41.7g, adjuvant Polyethylene Glycol-6000 22g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment eight
Get Radix Astragali 65.6g, Radix Salviae Miltiorrhizae 25.8g, Radix Notoginseng 9.5g, Lignum Dalbergiae Odoriferae 46.4g, adjuvant Polyethylene Glycol-6000 35g makes Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment nine
Get Radix Astragali 35.5g, Radix Salviae Miltiorrhizae 50.8g, Radix Notoginseng 16.3g, Lignum Dalbergiae Odoriferae 52.3g, adjuvant Polyethylene Glycol-6000 35g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Claims (4)
1. QISHEN YIQI DIWAN is prevented and treated application in the high altitude anoxia medicine in preparation.
2. QISHEN YIQI DIWAN according to claim 1 is prevented and treated application in the high altitude anoxia medicine in preparation, it is characterized in that, described QISHEN YIQI DIWAN is to be prepared from by following component by weight percentage: the Radix Astragali 22.2%～66.8%, Radix Salviae Miltiorrhizae 11.6%～33.4%, Radix Notoginseng 2.5%～13.5%, Lignum Dalbergiae Odoriferae 14.5%～44.3%.
3. QISHEN YIQI DIWAN according to claim 2 is prevented and treated application in the high altitude anoxia medicine in preparation, it is characterized in that described QISHEN YIQI DIWAN is to be prepared from by following component by weight percentage: the Radix Astragali 44.7%, Radix Salviae Miltiorrhizae 26.7%, Radix Notoginseng 6.3%, Lignum Dalbergiae Odoriferae 22.3%.
4. QISHEN YIQI DIWAN according to claim 2 is prevented and treated application in the high altitude anoxia medicine in preparation, it is characterized in that described QISHEN YIQI DIWAN is to be prepared from by following component by weight percentage: the Radix Astragali 41.2%, Radix Salviae Miltiorrhizae 23.8%, Radix Notoginseng 4.5%, Lignum Dalbergiae Odoriferae 30.5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100135067A CN1861114B (en) | 2005-05-13 | 2005-05-13 | Application of Qishen Yiqi dripping pills for preparing medicine for preventing and treating high-altitude oxygen deficit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100135067A CN1861114B (en) | 2005-05-13 | 2005-05-13 | Application of Qishen Yiqi dripping pills for preparing medicine for preventing and treating high-altitude oxygen deficit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1861114A true CN1861114A (en) | 2006-11-15 |
| CN1861114B CN1861114B (en) | 2011-04-27 |
Family
ID=37388700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100135067A Active CN1861114B (en) | 2005-05-13 | 2005-05-13 | Application of Qishen Yiqi dripping pills for preparing medicine for preventing and treating high-altitude oxygen deficit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1861114B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012000425A1 (en) * | 2010-06-28 | 2012-01-05 | 天津天士力制药股份有限公司 | Use of a chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction |
| CN104839810A (en) * | 2015-03-30 | 2015-08-19 | 孙村镇中药材种植技术协会 | High-altitude hypoxia resistance enhancing partially fermented rhodiola rosea and Chinese wolfberry fruit juice and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1248702C (en) * | 2002-02-07 | 2006-04-05 | 天津天士力制药股份有限公司 | Chinese medicine prepn. for treating coronary heart disease and angina pactoris and its prepn. process |
-
2005
- 2005-05-13 CN CN2005100135067A patent/CN1861114B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012000425A1 (en) * | 2010-06-28 | 2012-01-05 | 天津天士力制药股份有限公司 | Use of a chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction |
| JP2013529655A (en) * | 2010-06-28 | 2013-07-22 | テースリー ファーマシューティカル グループ カンパニー リミテッド | Use of traditional Chinese medicine composition in the manufacture of medicine for secondary prevention treatment of myocardial infarction |
| US9211310B2 (en) | 2010-06-28 | 2015-12-15 | Tasly Pharmaceutical Group Co., Ltd | Use of a Chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction |
| CN104839810A (en) * | 2015-03-30 | 2015-08-19 | 孙村镇中药材种植技术协会 | High-altitude hypoxia resistance enhancing partially fermented rhodiola rosea and Chinese wolfberry fruit juice and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1861114B (en) | 2011-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6305407B2 (en) | Chinese medicine composition for regulating immunity and method for producing the same | |
| CN104645091A (en) | Capsule for treating hypertension | |
| CN102145128A (en) | Medicinal composition for preventing and treating cardiac and cerebral vascular diseases and preparation method thereof | |
| CN104983844A (en) | Edible composition formula with mucous-membrane restoring function and preparation process of preparation thereof | |
| CN1259955C (en) | Chinese medicine preparation for treating climacteric metancholia of women | |
| CN101028446A (en) | Medicine for symptomatic dry eye | |
| CN1861114B (en) | Application of Qishen Yiqi dripping pills for preparing medicine for preventing and treating high-altitude oxygen deficit | |
| CN101112236B (en) | Health products having a hypoxia-tolerance function | |
| CN1401365A (en) | Chinese health medicine | |
| CN1430982A (en) | Capsule of astragalus and honey as well as its preparing technique | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN102327304B (en) | Drug for preventing and controlling chronic mountain sickness and preparation method thereof | |
| CN105343506A (en) | Method for preparing composition for treating type-2 diabetes | |
| CN101066425A (en) | Chinese medicine prepn for treating ungual mycosis | |
| CN102727730B (en) | Traditional Chinese medicinal compound preparation for treating male infertility and its preparation method | |
| CN1217685C (en) | Chinese medicine for sub-health and its preparing method | |
| CN109045210A (en) | A kind of Chinese medicine composition and preparation method thereof for treating cardiovascular and cerebrovascular disease | |
| CN114767760B (en) | A composition with liver protecting effect | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN1195537C (en) | External-applied Chinese medicine for treating hypertension and its preparing process | |
| CN1240430C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing mthod thereof | |
| CN101244127B (en) | Medicament for treating vascular dementia | |
| CN1706462A (en) | Acne eliminating tablet and its prepn process | |
| CN1853711A (en) | Xinmaikangzhong Chinese medicinal composition and preparation thereof | |
| CN1895346A (en) | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP03 | Change of name, title or address |